Inspire is proud to partner with Pfizer on the launch of Super Genes—a bold new research initiative designed to identify and learn from people who possess rare genetic variations that may protect them from certain diseases.
By combining genomic science with real-world patient storytelling, Super Genes aims to unlock insights that could shape the next generation of targeted therapies and preventative treatments.
As part of this collaboration, Inspire is helping connect Pfizer with individuals across its 10+ million-member community who may have lived experiences that match genetic outlier profiles. Through storytelling and structured outreach, the initiative is designed to elevate patient voices and foster greater awareness of how everyday people may hold the key to extraordinary medical breakthroughs.
“Inspire is one of several advocacy partners supporting this work by helping to find and amplify stories of people whose lived experience could offer valuable clues”
Identifying Genetic Outliers to Advance Drug Discovery
The Super Genes initiative invites people who believe they might be living with protective genetic traits—such as not developing a condition despite strong family history—to share their stories. These stories may lead to future research partnerships, further genomic testing, or participation in health studies.
From natural resistance to rare diseases to unexpectedly long recovery times, these cases may hold secrets to entirely new treatment pathways.
Putting Patient Voice at the Center of Genomic Research
At the heart of this initiative is a desire to bring patients into the discovery process—not just as subjects, but as storytellers, collaborators, and co-creators. Inspire’s unique community model ensures that these voices are not only heard but supported and respected through every step.
Read the Full Article
To learn more about this initiative and how Inspire is helping patients contribute to genomic discovery, read the full story from Pfizer here:
Empowering People with Super Genes to Help Unlock New Treatment Pathways (Pfizer.com)